MediciNova to Participate at the 38th Annual ROTH Conference
Rhea-AI Summary
MediciNova (NASDAQ: MNOV) will participate in the 38th Annual ROTH Conference March 22–24, 2026 at The Ritz-Carlton, Dana Point, CA.
President & CEO Yuichi Iwaki, M.D., Ph.D., and Chief Business Officer David H. Crean, Ph.D., will hold in-person one-on-one and small group meetings to provide company updates; investors should contact ROTH representatives to arrange meetings.
Positive
- None.
Negative
- None.
News Market Reaction – MNOV
In the Mar 16 session, MNOV gained 7.41%, reflecting a notable positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. Trading volume was elevated at 2.0x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 29 | ALS EAP enrollment | Positive | -1.7% | ALS expanded-access program reached 100 of 200 planned patients enrolled. |
| Jan 06 | CEO strategic letter | Positive | +0.0% | CEO outlined 2025 clinical progress and key 2026 priorities across lead programs. |
| Dec 18 | OXTOX enrollment complete | Positive | -1.4% | Completed enrollment of 100 patients in Phase 2 OXTOX neuropathy prevention trial. |
| Dec 08 | COMBAT-ALS update | Positive | -3.2% | Presented Phase 2b/3 COMBAT-ALS baseline and enrollment completion at ALS/MND symposium. |
| Dec 01 | MN-001 Phase 2 status | Positive | +4.3% | Mechanistic MN-002 data and Phase 2 MN-001 enrollment completion in metabolic disease. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent clinical and program updates were generally positive but often met with flat to negative next-day moves; only one of five events showed a clearly positive price alignment.
Over the past six months, MediciNova has focused on late-stage clinical execution across MN‑166 and MN‑001. Updates included completion of enrollment in the OXTOX Phase 2 study and the MN‑001 Phase 2 trial, progress in the COMBAT‑ALS Phase 2b/3 trial with 234 patients randomized, and growth of the ALS expanded‑access program to 100 patients. Despite these steps, most related announcements saw muted or negative price reactions, framing today’s conference participation against a backdrop of cautious trading.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LA JOLLA, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D., Ph.D., President and CEO, and David H. Crean, Ph.D., Chief Business Officer will participate at the 38th Annual ROTH Conference. The conference is being held on March 22 – 24, 2026 at The Ritz-Carlton Laguna Niguel in Dana Point, CA.
Drs. Iwaki and Crean will host one-on-one and small group meetings with investors and provide company updates. Investors interested in arranging a meeting should contact their representatives at ROTH.
| Event: | 38th Annual ROTH Conference |
| Date: | March 22-24, 2026 |
| Location: | The Ritz-Carlton, Dana Point, CA |
| Format: | In-person 1x1 meetings |
For more information on the ROTH Conference please visit www.roth.com/conferences.
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has numerous programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
Forward-Looking Statements
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
INVESTOR CONTACT:
David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com
